Spots Global Cancer Trial Database for relapsed cancer
Every month we try and update this database with for relapsed cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | NCT04510636 | Classical Hodgk... Relapsed Cancer Refractory Canc... | Pembrolizumab Bendamustine Hy... | 18 Years - | University Health Network, Toronto | |
| PRecISion Medicine for Children With Cancer | NCT03336931 | Childhood Cance... Childhood Solid... Childhood Brain... Childhood Leuke... Refractory Canc... Relapsed Cancer | Molecular profi... | - 21 Years | Sydney Children's Hospitals Network | |
| Precision Medicine for Every Child With Cancer | NCT05504772 | Childhood Cance... Childhood Solid... Childhood Brain... Childhood Leuke... Refractory Canc... Relapsed Cancer | Whole Genome Se... RNA seq DNA Methylation Targeted Panel ... High Throughput... Patient Derived... Liquid Biopsy | 0 Years - 25 Years | Australian & New Zealand Children's Haematology/Oncology Group | |
| A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | NCT05662397 | Solid Tumor, Ad... Relapsed Cancer Refractory Canc... | HST-1011 Cemiplimab | 18 Years - | HotSpot Therapeutics, Inc | |
| Lorlatinib Combinations in Lung Cancer | NCT04292119 | Lung Cancer Anaplastic Lymp... ROS1 Rearrangem... Relapsed Cancer MET Amplificati... Resistant Cance... NSCLC | Lorlatinib Crizotinib Binimetinib TNO155 | 18 Years - | Massachusetts General Hospital | |
| A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) | NCT05641324 | Multiple Myelom... Relapsed Cancer Refractory Mult... Adult Disease Hematologic Dis... | ANV419 Lenalidomide wi... Daratumumab | 18 Years - | Anaveon AG | |
| Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents | NCT03765099 | Advanced Cancer Relapsed Cancer Refractory Canc... | Animal-Assisted... | 3 Years - 17 Years | Vanderbilt-Ingram Cancer Center | |
| Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers | NCT05302037 | Cancer Malignancy Refractory Canc... Relapsed Cancer | Allogeneic NKG2... | 21 Years - | CytoMed Therapeutics Pte Ltd | |
| Three Times Weekly Symptom Screening for Children With Cancer | NCT04275102 | Cancer Relapsed Cancer | SPARK | 8 Years - 18 Years | The Hospital for Sick Children | |
| Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS | NCT03187288 | Acute Myeloid L... Myelodysplastic... Relapsed Cancer Refractory Canc... | CFI-400945 Fuma... | 18 Years - | University Health Network, Toronto | |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | NCT05681195 | Primary Central... Secondary Centr... Relapsed Cancer Refractory Canc... | Pemetrexed Zanubrutinib Autologous Stem... Whole Brain Rad... | 18 Years - | Baptist Health South Florida | |
| Precision Medicine for Every Child With Cancer | NCT05504772 | Childhood Cance... Childhood Solid... Childhood Brain... Childhood Leuke... Refractory Canc... Relapsed Cancer | Whole Genome Se... RNA seq DNA Methylation Targeted Panel ... High Throughput... Patient Derived... Liquid Biopsy | 0 Years - 25 Years | Australian & New Zealand Children's Haematology/Oncology Group | |
| Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents | NCT04310345 | Advanced Cancer Relapsed Cancer Refractory Canc... | Animal-Assisted... | 8 Years - | Vanderbilt-Ingram Cancer Center | |
| Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059) | NCT01380184 | Cancer, Advance... | ridaforolimus | 18 Years - 75 Years | Merck Sharp & Dohme LLC | |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL | NCT04421560 | Primary Central... Recurrent Cance... Refractory Canc... Relapsed Cancer | Ibrutinib Pembrolizumab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | NCT05681195 | Primary Central... Secondary Centr... Relapsed Cancer Refractory Canc... | Pemetrexed Zanubrutinib Autologous Stem... Whole Brain Rad... | 18 Years - | Baptist Health South Florida | |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | NCT04510636 | Classical Hodgk... Relapsed Cancer Refractory Canc... | Pembrolizumab Bendamustine Hy... | 18 Years - | University Health Network, Toronto | |
| Individualized Treatments in Adults With Relapsed/Refractory Cancers | NCT06024603 | Refractory Canc... Relapsed Cancer | Drug Sensitivit... | 18 Years - | Case Comprehensive Cancer Center | |
| Plan Development for Giving Teclistamab in the Outpatient Setting | NCT06251076 | Multiple Myelom... Relapsed Cancer Refractory Canc... | Teclistamab Tocilizumab | 18 Years - | University Health Network, Toronto | |
| Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | NCT05852717 | Large Cell Lymp... Relapsed Cancer Refractory Canc... | AutoSCT OR CAR ... GDP Epcoritamab | 18 Years - | Hoosier Cancer Research Network | |
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | NCT04092179 | Acute Myeloid L... Relapsed Cancer Refractory Canc... IDH2 Gene Mutat... | Enasidenib Venetoclax | 18 Years - | University Health Network, Toronto | |
| Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma | NCT06430424 | Relapsed Cancer Glioblastoma ID... | Relapsed gliobl... | 18 Years - | University Hospital, Bordeaux | |
| Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma | NCT06430424 | Relapsed Cancer Glioblastoma ID... | Relapsed gliobl... | 18 Years - | University Hospital, Bordeaux |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
